Skip to content

OÜ PharmaEleven

Registry code (registrikood) 14915329Private limited company (Osaühing)VAT EE102233791Activity (EMTAK 47731): Ravimite jaemüükActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€4.0M
▲ 64.8% vs 2024
Profit before tax (2025)
-€41k
Employees, FTE (2025)
5
State taxes paid, last 4 quarters
€45k

Revenue, profit and employees, 2020–2025

€1.3M2020€1.7M2021€1.8M2022€2.0M2023€2.4M2024€4.0M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2020€1,319,082-€214,895-€214,895-€212,3952
2021€1,677,323-€77,859-€77,859-€290,2541
2022€1,803,521-€151,105-€151,104-€441,3573
2023€1,988,489-€140,185-€140,184-€581,5414
2024€2,444,566-€26,235-€26,274-€607,8153
2025€4,029,336-€40,882-€40,879-€648,6945

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2020€22,308€994,029€1,206,424—-€212,395
2021€19,071€872,113€1,162,367—-€290,254
2022€60,277€863,712€1,305,069—-€441,357
2023€22,161€307,417€888,958—-€581,541
2024€92,620€909,811€1,517,626—-€607,815
2025€86,924€841,346€1,490,040—-€648,694

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€0€2,180€378,3504
2022 Q2€0€4,805€462,7184
2022 Q3€5,333€12,828€416,2704
2022 Q4€6,291€12,919€496,5804
2023 Q1€6,263€14,124€499,8994
2023 Q2€5,726€13,908€477,7244
2023 Q3€10,589€18,583€415,7835
2023 Q4€6,658€15,760€608,6885
2024 Q1€0€11,785€454,1016
2024 Q2€3,173€11,679€490,4938
2024 Q3€6,196€12,896€414,6246
2024 Q4€4,821€13,571€848,4069
2025 Q1€7,733€18,980€1,035,53811
2025 Q2€9,487€20,542€993,17611
2025 Q3€9,244€19,575€899,09413
2025 Q4€9,826€20,767€1,089,65014
2026 Q1€13,927€20,337€1,110,06613
2026 Q2€8,627€18,505€998,59813
2026 Q3€12,663€18,940€927,26415

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), OÜ PharmaEleven reported revenue of €4,029,336.

The company recorded a net loss of €40,879 in the 2025 financial year.

Revenue increased by 64.8% from €2,444,566 in 2024 to €4,029,336 in 2025.

Revenue grew at a compound annual rate of 25.0% between 2020 and 2025.

Equity accounted for -77.1% of total assets of €841,346 at the end of the 2025 reporting period.

With 5 full-time-equivalent employees in 2025, revenue per employee was €805,867.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, OÜ PharmaEleven reported €4,125,578 in turnover.

EMTA recorded 15 employees for the quarter ending Q3 2026, compared with 5 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.